HC Wainwright & Co. Downgrades Taro Pharmaceutical Indus to Neutral, Maintains Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has downgraded Taro Pharmaceutical Industries (NYSE:TARO) from Buy to Neutral while maintaining the price target at $43.

January 18, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Taro Pharmaceutical has been downgraded by HC Wainwright & Co. from Buy to Neutral, but the price target remains unchanged at $43.
The downgrade to Neutral suggests a more cautious view on the stock by the analyst, which could lead to a tempered investor sentiment in the short term. However, since the price target was not adjusted, this indicates that the fundamental value assessment of the company has not significantly changed. This mixed signal may result in a neutral short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100